High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

TUESDAY, Aug. 19, 2025 -- Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study published online Aug. 14 in Nature Medicine.

Kari L. Kendra, M.D., Ph.D., from The Ohio State University Wexner Medical Center in Columbus, examined the activity of pembrolizumab in patients with surgically unresectable desmoplastic melanoma in a single-arm clinical trial, which enrolled 27 patients who received pembrolizumab 200 mg intravenously every three weeks for up to two years.

The researchers found that the complete response rate was 37 percent and the post-hoc end point of objective response rate was 89 percent. In terms of estimated secondary end points, three-year melanoma-specific progression-free survival was 84 percent and overall survival was 96 percent; one patient died of melanoma progression. Overall, 10 and nine patients (37 and 33 percent) experienced grade 3 to 4 adverse events and discontinued treatment due to adverse events, respectively.

"The promising results from this trial show that pembrolizumab can offer durable benefit for patients with a melanoma subtype that previously had no successful treatment options, and now we know that desmoplastic melanoma is among the cancers with the highest response rates to the anti-PD-1 class of cancer immunotherapies," senior author Antoni Ribas, M.D., Ph.D., from the University of California, Los Angeles, said in a statement.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-20 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords